Skip to main content
SpringerLink
Log in

Renal Cell Carcinoma

  • Conference paper
Biological Modulation of Solid Tumours by Interferons

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 33 Accesses

Abstract

Metastatic renal cell carcinoma (RCC) is at present an incurable disease. The median survival time for patients with metastatic RCC is approximately 10 months with less than 10% of patients surviving for 2 years [1]. This poor prognosis depends on the fact that conventional therapy is ineffective, with an objective response rate of less than 20% for hormonal and chemotherapeutic agents given either alone or in combination [2]. These disappointing results, the recent availability of recombinant cytokines and the fact that spontaneous regressions of RCC (presumably mediated by the host immune response) have been reported, have spawned interest in the immunobiology of RCC with the aim of understanding the immunological relationship between the host and the tumour, and evaluating whether immunotherapy could represent a novel approach to this malignancy. Interferons (IFNs), in particular, have been investigated in the treatment of advanced RCC either as a single agent or in combination with cytotoxic drugs or other cytokines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. deKernion JB, Ramming KP, Smith RB: The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978 (120):148–152

    Google Scholar 

  2. Reese JH: Renal cell carcinoma. Curr Opin Oncol 1992(4):427–434

    Google Scholar 

  3. Beniers AJMC, Peelen WP, Debruyne FMJ, Schalken JA: HLA-cIass-l and-class-ll expression on renal tumor xenografts and the relation to sensitivity for IFN-α, IFN-γ and TNF. Int J Cancer 1991 (48):709–716

    Google Scholar 

  4. Mattijssen V, Van Moorselaar J, De Mulder PH, Schalkwijk L, Ruiter DJ: Human leucocyte antigen expression in renal cell carcinoma lesions does not predict the response to interferon therapy. J Immunother 1992 (12):64–69

    Google Scholar 

  5. Tornita Y, Nishiyama T, Watanabe H, Fujiwara M, Sato S: Expression of intercellular adhesion molecule-1 (ICAM-1) on renal-cell cancer: possible significance in host immune responses. Int J Cancer 1990 (46):1001–1006

    Google Scholar 

  6. Belldegrun A, Muul LM, Rosenberg SA: Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization and antitumor activity. Cancer Res 1988 (48):206–214

    Google Scholar 

  7. Finke JH, Rayman P, Alexander J, Edinger M, Tubbs RR, Connelly R, Pontes E, Bukowski R: Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 1990 (50):2363–2370

    Google Scholar 

  8. Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP: Antiproliferative and antitumor effects of a-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res 1990 (50):4190–4194

    Google Scholar 

  9. Eisenkraft BL, Nanus DM, Albino AP, Pfeffer LM: a-interferon down-regulates epidermal growth factor receptors on renal carcinoma cells: relation to cellular responsiveness to the antiproliferative action of a-interferon. Cancer Res 1991 (51):5881–5887

    Google Scholar 

  10. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T: 1L-6 functions as an autocrine growth factor in renal cell carcinoma. FEBS Lett 1989 (250):607–610

    Google Scholar 

  11. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Rovault A, Tourani JM, Moskovtchenko JF, Philip T: Serum level of IL-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992 (52):3317–3322

    Google Scholar 

  12. Gruss HJ, Brach MA, Mertelsmann RH, Herrmann F: Interferon-y interrupts autocrine growth mediated by endogenous IL-6 in renal cell carcinoma. Int J Cancer 1991 (49):770–773

    Google Scholar 

  13. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990 (50):3473–3486

    Google Scholar 

  14. Parmiani G, Rivoltini L: Biologic agents as modifiers of chemotherapeutic effects. Curr Opin Oncol 1991 (3):1078–1086

    Google Scholar 

  15. Neidhart JA, Anderson SA, Harris JE, Rinehart JJ, Laszlo J, Dexeus FH, Einhorn LH, Trump DL, Benedetto PW, Tuttle RL, Smalley RV: Vinblastine fails to improve response of renal cancer to interferon-α-n1: high response rate in patients with pulmonary metastases. J Clin Oncol 1991 (9):832–837

    Google Scholar 

  16. Brunda MJ, Bellantoni D, Sulich V: In vivo anti-tumor activity of combinations of IFN α and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987 (40):365–371

    Google Scholar 

  17. Cameron RB, Mcintosh JK, Rosenberg SA: Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid a-interferon in the treatment of established murine hepatic metastases. Cancer Res 1988 (48):5810–5817

    Google Scholar 

  18. Hoon DS, Okun E, Banez M, Irie RF, Morton DL: lnterleukin-4 alone and with y-interferon or a-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinoma. Cancer Res 1991 (51):5687–5693

    Google Scholar 

  19. Beniers AJMC, Peelen WP, Hendriks BT, Schalken JA, Debruyne FMJ: Effect of a-and y-interferon and tumor necrosis factor on colony formation of two human renal tumor xenografts in vitro. Sem Surg Oncol 1988 (4):195–198

    Google Scholar 

  20. Sayers TJ, Wiltrout TA, McCormick K, Husted C, Wiltrout RH: Antitumor effects of a-interferon and γ-interferon on a murine renal cancer (Renca) in vitro and in vivo. Cancer Res 1990 (50):5414–5420

    Google Scholar 

  21. Hannigan GE, Fish EN, Williams BRG: Modulation of human interferon α receptor expression by human interferon γ. J Biol Chem 1984 (259):8084–8086

    Google Scholar 

  22. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, Bander NH, Gansbacher B: Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 1992 (52):6229–6236

    Google Scholar 

  23. deKernion JB, Sarna G, Figlin RA, Lindner A, Smith RB: The treatment of renal cell carcinoma with human leucocyte α-interferon. J Urol 1983 (130):1063–1066

    Google Scholar 

  24. Quesada JR, Swanson DA, Trindade A, Gutterman JU: Renal cell carcinoma: antitumor effects of leucocyte interferon. Cancer Res 1983 (43):940–947

    Google Scholar 

  25. Kirkwood JM, Harris JE, Vera R, Sandler S, Fischer DS, Khaudekar J, Emstoff MS, Gordon L, Lutes R, Bonomi P, Lytton B, Cobleigh M, Taylor IV SJ: A randomized study of low and high doses of leukocyte α-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 1985 (45):863–873

    Google Scholar 

  26. Umeda T, Niijima T: Phase II study of a-interferon on renal cell carcinoma. Cancer 1986 (58):1231–1235

    Google Scholar 

  27. Kempf RA, Grunberg SM, Daniels JR, Skinner DG, Venturi CL, Spiegel R, Neri R, Greiner JM, Rudnick S, Mitchell MS: Recombinant interferon a-2 (INTRON A) in a phase II study of renal cell carcinoma. J Biol Resp Modif 1986(5):27–35

    Google Scholar 

  28. Sarna G, Figlin R, deKernion J: Interferon in renal cell carcinoma. The UCLA experience. Cancer 1987 (59):610–612

    Google Scholar 

  29. Figlin RA, deKernion JB, Mukamel E, Palleroni AV, Itri LM, Sarna GP: Recombinant Interferon a-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-lnterferon antibody formation. J Clin Oncol 1988 (6):1604–1610

    Google Scholar 

  30. Fujita T, Asano H, Naide Y, Ono Y, Ohshima S, Suzuki K, Aso Y, Ariyoshi Y, Fukushima M, Ota K: Antitumor effects of human lymphoblastoid interferon on advanced renal cell carcinoma. J Urol 1988(139):256–258

    Google Scholar 

  31. Retsas S, Bafaloukos D, Brunt AM: α-interferons: impact on survival of patients with renal cell carcinoma. Clin Oncol 1991 (3):273–277

    Google Scholar 

  32. Kosmidis PA, Baxevanis CN, Tsavaris N, Papanastasiou M, An astaso poulos E, Bacoyiannis C, Mylonakis N, Karvounis N, Bafaloukos D, Karabelis A, Papamichail M: The prognostic significance of immune changes in patients with RCC treated with interferon-α2b. J Clin Oncol 1992 (10):1153–1157

    Google Scholar 

  33. Kinney P, Triozzi P, Young D, Drago J, Behrens B, Wise H, Rinehart JJ: Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma. J Clin Oncol 1990 (8):881–885

    Google Scholar 

  34. Rinehart JJ, Malspies L, Young D, Neidhart JA: Phase l/lI trial of human recombinant interferon γ in renal cell carcinoma. J Biol Resp Modif 1986 (5):300–308

    Google Scholar 

  35. Garnick MB, Reich SD, Maxwell B, Coval-Goldsmith S, Richie JP, Rudnick SA: Phase l/ll study of recombinant interferon γ in advanced renal cell carcinoma. J Urol 1988 (139):251–255

    Google Scholar 

  36. Aulitzky W, Gastl G, Aulitzky WE, Herold M, Kemmler J, Mull B, Frick J, Huber C: Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-γ. J Clin Oncol 1989 (7):1875–1884

    Google Scholar 

  37. Ernstoff MS, Nair S, Bahnson RR, Miketic LM, Banner B, Gooding W, Day R, Whiteside T, Hakala T, Kirkwood JM: A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon γ and recombinant interferon α in patients with metastatic renal cell carcinoma. J Clin Oncol 1990 (8):1637–1649

    Google Scholar 

  38. Muss HB: The use of interferon in renal cell carcinoma. Eur J Cancer 1991 (27,S):84–87

    Google Scholar 

  39. Wadler S: The role of interferons in the treatment of solid tumors. Cancer 1992 (70,S):949–958

    Google Scholar 

  40. Feruglio C, Zambello R, Trentin L, Bulian P, Franceschi T, Cetto GL, Semenzaio G: Cytotoxic in vitro function in patients with metastatic RCC before and after α-2b-interferon therapy. Cancer 1992 (69):2525–2531

    Google Scholar 

  41. Atzpodien J, Poliwoda H, Kirchner H: α-interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. Sem Oncol 1991 (18,S):108–112

    Google Scholar 

  42. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J: Concomitant administration of recombinant human interleukin-2 and recombinant interferon α-2a: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992 (10):414–421

    Google Scholar 

  43. Pichert G, Jost LM, Fierz W, Stahel RA: Clinical and immune modulatory effects of alternative weekly interleukin-2 and IFN-α-2a in patients with advanced renal cell carcinoma and melanoma. Br J Cancer 1991 (63):287–292

    Google Scholar 

  44. Quesada JR, Evans L, Saks SR, Gutterman JU: Recombinant interferon α and γ in combination as treatment for metastatic renal cell carcinoma. J Biol Resp Modif 1988 (7):234–239

    Google Scholar 

  45. Emstoff MS, Gooding W, Nair S, Bahnson RR, Miketic LM, Banner B, Day R, Whiteside T, Titus-Ernstoff L, Kirkwood JM: Immunological effects of treatment with sequential administration of recombinant interferon γ and α in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res 1992 (52):851–856

    Google Scholar 

  46. Parmiani G, Anichini A, Fossati G: Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? JNC 1990 (82):361–370

    Google Scholar 

  47. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G: Melanoma cells and normal melanocytes share antigens recognized by HLA-A2 restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993(177):989–998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Experimental Oncology D, Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy

    P. A. Ruffini & C. Gambacorti-Passerini

Authors
  1. P. A. Ruffini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Gambacorti-Passerini
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinik für Urologie, Auenbruggerplatz 1, 8036, Graz, Austria

    Karl Pummer M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Ruffini, P.A., Gambacorti-Passerini, C. (1994). Renal Cell Carcinoma. In: Pummer, K. (eds) Biological Modulation of Solid Tumours by Interferons. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78866-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78866-6_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-78868-0

  • Online ISBN: 978-3-642-78866-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation